Genome-wide association study meta-analysis of suicide attempt in 43,871 cases identifies twelve genome-wide significant loci

Anna R Docherty, PhD[1,2,3]*†, Niamh Mullins, PhD[4,5]*, Allison E Ashley-Koch, PhD[6]*, Xuejun Qin, PhD[6], Jonathan R I Coleman, PhD[7,8], Andrey Shabalin, PhD[1,2], JooEun Kang, PhD[9], Balasz Murnyak, PhD[1,2], Frank Wendt, PhD[10], Mark Adams, PhD[11], Adrian I Campos, PhD[12,13], Emily DiBlasi, PhD[1,2], Janice M Fullerton, PhD[14,15], Henry R Kranzler, MD[16,17], Amanda Bakian[2], Eric T Monson, MD, PhD[2], Miguel E Rentería, PhD[12,18], Consuelo Walss-Bass, PhD[19], Ole A Andreassen, MD, PhD[20,21], Cynthia M Bulik, PhD[22,23,24], Howard J Edenberg, PhD[25,26], Ronald C Kessler, PhD[27], J John Mann, MD[28], John I Nurnberger Jr., MD, PhD[29,29], Giorgio Pistis, PhD[30], Fabian Streit, PhD[31], Robert J Ursano, MD[32], Renato Polimonti, PhD[10], Michelle Dennis, BS[33], Melanie Garrett, MS[34], Lauren Hair, MS[35], Philip Harvey, PhD[36], Elizabeth R Hauser, PhD[6,37], Michael A Hauser, PhD[6], Jennifer Huffman, PhD[38], Daniel Jacobson, PhD[39], Jennifer H Lindquist, MS, M Stat[40], Ravi Madduri, MS[41], Benjamin McMahon, PhD[42], David W Oslin, MD[43,44], Jodie Trafton, PhD[45], Swapnil Awasthi, MSc[46], Andrew W Bergen, PhD[47,48], Wade H Berrettini, MD, PhD[49], Martin Bohus, MD[50], Harry Brandt, MD[51,52], Xiao Chang, PhD[53], Hsi-Chung Chen, MD, PhD[54], Wei J Chen, MD, PhD[54,55,56], Erik D Christensen, MD[57,58], Steven Crawford, MD[51,52], Scott Crow, MD[59], Philibert Duriez, MD[60,61], Alexis C Edwards, PhD[3], Fernando Fernández-Aranda, PhD[62], Manfred M Fichter, MD[63,64], Hanga Galfalvy, PhD[65,66], Steven Gallinger, MD[67], Michael Gandal, PhD[68], Philip Gorwood, MD, PhD[60,61], Yiran Guo, PhD[53], Jonathan D Hafferty, MBChB[11], Hakon Hakonarson, MD, PhD[53,69], Katherine A Halmi, MD[70], Akitoyo Hishimoto, MD, PhD[71], Sonia Jain, PhD[72], Stéphane Jamain, PhD[73], Susana Jiménez-Murcia, PhD[62], Craig Johnson, PhD[74], Allan S Kaplan, MD, FRCP(C)[75,76,77], Walter H Kaye, MD[78], Pamela K Keel, PhD[79], James L Kennedy, MD, FRCP(C)[75,76,77], Minsoo Kim, BS[68], Kelly L Klump, PhD[80], Daniel F Levey, PhD[81,82], Dong Li, PhD[53], Shih-Cheng Liao, PhD[54], Klaus Lieb, MD[83], Lisa Lilenfeld, PhD[84], Adriana Lori, PhD[85], Pierre J Magistretti, MD, PhD[86,87], Christian R Marshall, PhD[88], James E Mitchell, MD[89], Richard M Myers, PhD[90], Satoshi Okazaki, MD, PhD[91], Ikuo Otsuka, MD, PhD[66,91], Dalila Pinto, PhD[4,5], Abigail Powers, PhD, ABPP[85], Nicolas Ramoz, PhD[61], Stephan Ripke, MD, PhD[46,92,93], Stefan Roepke, MD[94], Vsevolod Rozanov, MD, PhD[95,96], Stephen W Scherer, PhD, FRSC[97,98], Christian Schmahl, MD[50], Marcus Sokolowski, PhD[99], Anna Starnawska, PhD[100,101,102,103], Michael Strober, PhD[104,105], Mei-Hsin Su, PhD[56], Laura M Thornton, PhD[24], Janet Treasure, PhD, FRCP[106,107], Erin B Ware, PhD, MPH[108,109], Hunna J Watson, PhD[24,110,111], Stephanie H Witt, PhD[31], D Blake Woodside, MD[76,77,112,113], Zeynep Yilmaz, PhD[24,114,115], Lea Zillich, MSc[31], Rolf Adolfsson, PhD[116], Ingrid Agartz, MD, PhD[117,118,119], Tracy M Air, MSc[120], Martin Alda, MD[121,122], Lars Alfredsson[123,124], Adebayo Anjorin, MRCPsych[125], Vivek Appadurai[126,127], María Soler Artigas, PhD[128,129,130,131], Sandra Van der Auwera, PhD[132,133], M Helena Azevedo, PhD[134], Nicholas Bass, MRCPsych[135], Claiton HD Bau, PhD[136,137], Bernhard T Baune, PhD[138,139], Frank Bellivier, PhD[140,141,142,143], Klaus Berger, MD[144], Joanna M Biernacka, PhD[145], Tim B Bigdeli, PhD[3,146], Elisabeth B Binder, PhD[85,147], Michael Boehnke, PhD[148], Marco P Boks, PhD[149], Rosa Bosch, BSc[128,129,150], David L Braff, MD[151], Richard Bryant, PhD[152], Monika Budde, Dipl-Psych[153], Enda M Byrne, PhD[13,154], Wiepke Cahn, PhD[155], Miguel Casas, MD, PhD[128,129,131,150], Enrique Castelao, MSc[30], Jorge A Cervilla, MD, PhD[156], Boris Chaumette, MD, PhD[157,158,159], Sven Cichon, PhD[160,161,162,163], Aiden Corvin, PhD[164], Nicholas Craddock, PhD[165], David Craig, PhD[166], Franziska Degenhardt, MD[163], Srdjan Djurovic, PhD[167,168], Ayman H Fanous, MD[3,146], Jerome C Foo, PhD[169], Andreas J Forstner, MD[160,163,170], Mark Frye, MD[171], Justine M Gatt, PhD[14,152], Pablo V Gejman, MD[172,173], Ina Giegling, PhD[174,175], Hans J Grabe, MD[132,133], Melissa J Green, PhD[14,176], Eugenio H Grevet, PhD[177,178], Maria Grigoroiu-Serbanescu, PhD[179], Blanca Gutierrez, PhD[180], Jose Guzman-Parra, PhD[181], Steven P Hamilton, MD[182], Marian L Hamshere, PhD[165], Annette M Hartmann, PhD[174], Joanna Hauser, PhD[183], Stefanie Heilmann-Heimbach, PhD[163], Per Hoffmann, PhD[161,162,163], Marcus Ising, PhD[184], Ian Jones, PhD[165], Lisa A Jones, PhD[185], Lina Jonsson, PhD[186], René S Kahn, MD, PhD[5,187], John R Kelsoe, MD[151,188], Kenneth S Kendler, MD[3], Stefan Kloiber, MD[75,184,189], Karestan C Koenen, PhD[92,190,191], Manolis Kogevinas, PhD[192], Bettina Konte, MSc[174], Marie-Odile Krebs, MD, PhD[157,158,159], Mikael Landén, MD, PhD[22,193], Jacob Lawrence, MRCPsych[194], Marion Leboyer, PhD[195,196,197], Phil H Lee, PhD[92,93,198], Douglas F Levinson, MD[199], Calwing Liao, PhD[200,201], Jolanta Lissowska, PhD[202], Susanne Lucae, PhD[184], Fermin Mayoral, PhD[181], Susan L McElroy, MD[203], Patrick McGrath, MD[204], Peter McGuffin, PhD[8], Andrew McQuillin, PhD[135], Divya Mehta, PhD[205,206], Ingrid Melle, MD, PhD[20,207], Yuri Milaneschi, PhD[208], Philip B Mitchell, MD[176], Esther Molina, PhD[209], Gunnar Morken,

PhD[210,211], Preben Bo Mortensen, MD[101,114,127,212], Bertram Müller-Myhsok, PhD[147,213,214], Caroline Nievergelt[151], Vishwajit Nimgaonkar, PhD[215], Markus M Nöthen, MD[163], Michael C O'Donovan, FRCPsych, PhD[165], Roel A Ophoff, PhD[68,216], Michael J Owen, FRCPsych, PhD[165], Carlos Pato, MD, PhD[217,217], Michele T Pato, MD[218], Brenda WJH Penninx, PhD[219], Jonathan Pimm, MRCPsych[135], James B Potash, MD[220], Robert A Power, PhD[8,221,222], Martin Preisig, MD[30], Digby Quested, MD[223], Josep Antoni Ramos-Quiroga, MD, PhD[128,129,131,150], Andreas Reif, MD[224], Marta Ribasés, PhD[128,129,130,131], Vanesa Richarte, MD, PhD[128,129,150], Marcella Rietschel, MD[225], Margarita Rivera, PhD[8,226], Andrea Roberts, MPH, PhD[227], Gloria Roberts, PhD[176], Guy A Rouleau, PhD[228,229], Diego L Rovaris, PhD[230], Dan Rujescu, MD[174], Cristina Sánchez-Mora, PhD[128,129,130,131], Alan R Sanders, MD[172,173], Peter R Schofield, PhD, DSc[14,15], Thomas G Schulze, MD[153,169,231,232,233], Laura J Scott, PhD[148], Alessandro Serretti, MD[234], Jianxin Shi, PhD[235], Stanley I Shyn, PhD[236], Lea Sirignano, MSc[169], Pamela Sklar, PhD[4,5,237], Olav B Smeland, MD, PhD[20,21], Jordan W Smoller, MD, ScD[92,191,238], Edmund J S Sonuga-Barke, PhD[239], Gianfranco Spalletta, MD, PhD[240,241], John S Strauss, MD[75,189], Beata Świątkowska, PhD[242], Maciej Trzaskowski, PhD[13], Ming T Tsuang[243], Gustavo Turecki, PhD[244], Laura Vilar-Ribó, BSc[128,131], John B Vincent, PhD[245], Henry Völzke, MD[246], James TR Walters, PhD[165], Cynthia Shannon Weickert, PhD[14,176], Thomas W Weickert, PhD[14,176], Myrna M Weissman, PhD[247,248], Leanne M Williams, PhD[249], Naomi R Wray, PhD[13,206], Clement C Zai, PhD[92,189,190,250,251,252], Esben Agerbo, DrMedSc[114,212,253], Anders D Børglum, PhD[100,101,102,103], Gerome Breen, PhD[7,8], Ditte Demontis, PhD[100,101,102,103], Annette Erlangsen, PhD[103,254,255,256], Tõnu Esko, PhD[257,258], Joel Gelernter, MD[81,82], Stephen J Glatt[259], David M Hougaard, MD[253,260], Hai-Gwo Hwu[261], Po-Hsiu Kuo[54,56], Cathryn M Lewis, PhD[8,262], Qingqin S Li, PhD[263], Chih-Min Liu[54], Nicholas G Martin, PhD[12], Andrew M McIntosh, MD[11], Sarah E Medland, PhD[12], Ole Mors, PhD[253,264], Merete Nordentoft, MD[253,265], Catherine M Olsen, PhD[266], David Porteous, PhD[267], Daniel J Smith, MD, FRCPsych[268], Eli A Stahl, PhD[4,257,269], Murray B Stein, MD, MPH[270], Danuta Wasserman, MD, PhD[99], Thomas Werge, PhD[126,253,271,272], David C Whiteman, MBBS, PhD[266], Virginia Willour, PhD[273], the VA Million Veteran Program (MVP), the MVP Suicide Exemplar Workgroup, Suicide Working Group of the Psychiatric Genomics Consortium, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Bipolar Disorder Working Group of the Psychiatric Genomics Consortium, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Eating Disorder Working Group of the Psychiatric Genomics Consortium, German Borderline Genomics Consortium, Hilary Coon, PhD[1,2,274], Jean C Beckham, PhD[275,276‡], Nathan A Kimbrel, PhD[275,276‡], Douglas M Ruderfer, PhD[9,277,278‡]

* These authors have contributed equally.

† Corresponding author

‡ Senior authors

1 Huntsman Mental Health Institute, Salt Lake City, UT, USA

2 University of Utah School of Medicine, Department of Psychiatry, Salt Lake City, UT, USA

3 Virginia Commonwealth University, Department of Psychiatry, Richmond, VA, USA

4 Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York, NY, USA

5 Icahn School of Medicine at Mount Sinai, Department of Psychiatry, New York, NY, USA

6 Duke University Medical Center, Duke Molecular Physiology Institute, Durham, NC, USA

7 King's College London, National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK

8 King's College London, Social Genetic and Developmental Psychiatry Centre, London, UK

9 Vanderbilt University Medical Center, Division of Genetic Medicine, Department of Medicine, Vanderbilt Genetics Institute, Nashville, TN, USA

10 Yale University School of Medicine, Department of Psychiatry, New Haven, CT, USA

11 University of Edinburgh, Division of Psychiatry, Edinburgh, UK

12 QIMR Berghofer Medical Research Institute, Mental Health and Neuroscience Research Program, Brisbane, QLD, Australia

13 The University of Queensland, Institute for Molecular Bioscience, Brisbane, QLD, Australia

14 Neuroscience Research Australia, Sydney, NSW, Australia

15 University of New South Wales, School of Medical Sciences, Sydney, NSW, Australia

16 University of Pennsylvania Perelman School of Medicine, Department of Psychiatry, Philadelphia, PA,

USA

[17] Crescenz VAMC, VISN 4 MIRECC, Philadelphia, PA, USA

[18] The University of Queensland, School of Biomedical Sciences, Faculty of Medicine, Brisbane, QLD, Australia

[19] University of Texas Health Science Center, Department of Psychiatry and Behavioral Sciences, Houston, TX, USA

[20] Oslo University Hospital, Division of Mental Health and Addiction, Oslo, Norway

[21] University of Oslo, NORMENT, Oslo, Norway

[22] Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden

[23] University of North Carolina at Chapel Hill, Department of Nutrition, Chapel Hill, NC, USA

[24] University of North Carolina at Chapel Hill, Department of Psychiatry, Chapel Hill, NC, USA

[25] Indiana University, Department of Medical & Molecular Genetics, Indianapolis, IN, USA

[26] Indiana University School of Medicine, Biochemistry and Molecular Biology, Indianapolis, IN, USA

[27] Harvard Medical School, Department of Health Care Policy, Boston, MA, USA

[28] Columbia University, Departments of Psychiatry and Radiology, New York, NY, USA

[29] Indiana University School of Medicine, Departments of Psychiatry and Medical and Molecular Genetics, Indianapolis, IN, USA

[30] Lausanne University Hospital and University of Lausanne, Department of Psychiatry, Lausanne, Vaud, Switzerland

[31] Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Department of Genetic Epidemiology in Psychiatry, Mannheim, Germany

[32] Uniformed University of the Health Sciences, Department of Psychiatry, Bethesda, MD, USA

[33] Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, Durham, NC, USA

[34] Duke University Medical Center, Durham, NC, USA

[35] Durham Veterans Affairs Health Care System, Durham, NC, USA

[36] Miami VA Health Care System, Miami, FL, USA

[37] Durham Veterans Affairs Health Care System, Cooperative Studies Program Epidemiology Center, Durham, NC, USA

[38] Boston VA Health Care System, Boston, MA, USA

[39] Oak Ridge National Laboratory, Oak Ridge, TN, USA

[40] Durham Veterans Affairs Health Care System, VA Health Services Research and Development Center of Innovation to Accelerate Discovery and Practice Transformation, Durham, NC, USA

[41] Argonne National Laboratory, University of Chicago Consortium for Advanced Science and Engineering, Chicago, IL, USA

[42] Los Alamos National Laboratory, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA

[43] Corporal Michael J. Crescenz VA Medical Center, VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia, PA, USA

[44] Perelman School of Medicine, University of Pennsylvania, Department of Psychiatry, Philadelphia, PA, USA

[45] VA Palo Alto Health Care System, VA Program Evaluation and Resource Center, Palo Alto, CA, USA

[46] Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Berlin, Germany

[47] BioRealm, LLC, Walnut, CA, USA

[48] Oregon Research Institute, Eugene, OR, USA

[49] Perelman School of Medicine at the University of Pennsylvania, Department of Psychiatry, Center for Neurobiology and Behavior, Philadelphia, PA, USA

[50] Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Department of Psychosomatic Medicine and Psychotherapy, Mannheim, Germany

[51] ERCPathlight, Baltimore, MD, USA

[52] University of Maryland St. Joseph Medical Center, Baltimore, MD, USA

[53] Children's Hospital of Philadelphia, Center for Applied Genomics, Philadelphia, PA, USA

[54] National Taiwan University Hospital, Department of Psychiatry, Taipei, Taiwan

[55] National Health Research Institutes, Center for Neuropsychiatric Research, Miaoli County, Taiwan

[56] National Taiwan University, Institute of Epidemiology and Preventive Medicine, College of Public Health, Taipei, Taiwan

[57] Utah Department of Health and Human Services, Utah Office of the Medical Examiner, Taylorsville, UT,

USA

[58] University of Utah, Department of Pathology, Salt Lake City, UT, USA

[59] University of Minnesota, Department of Psychiatry, Minneapolis, MN, USA

[60] GHU Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, Paris, France

[61] Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France

[62] University Hospital Bellvitge-IDIBELL and CIBEROBN, Department of Psychiatry, Barcelona, Spain

[63] Ludwig-Maximilians-University (LMU), Department of Psychiatry and Psychotherapy, Munich, Germany

[64] Schön Klinik Roseneck affiliated with the Medical Faculty of the University of Munich (LMU), Munich, Germany

[65] Columbia University, Department of Biostatistics, New York, NY, USA

[66] Columbia University, Department of Psychiatry, New York, NY, USA

[67] University of Toronto, Department of Surgery, Faculty of Medicine, Toronto, Canada

[68] University of California, Los Angeles, Department of Psychiatry and Biobehavioral Science, Semel Institute, David Geffen School of Medicine, Los Angeles, CA, USA

[69] University of Pennsylvania, The Perelman School of Medicine, Philadelphia, PA, USA

[70] Weill Cornell Medical College, Department of Psychiatry, New York, NY, USA

[71] Yokohama City University Graduate School of Medicine, Department of Psychiatry, Yokohama, Japan

[72] University of California San Diego, Biostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, La Jolla, CA, USA

[73] Univ Paris-Est-Créteil, INSERM, IMRB, Translational Neuropsychiatry, Fondation FondaMental, Créteil, France

[74] Eating Recovery Center, Denver, CO, USA

[75] Centre for Addiction and Mental Health, Toronto, ON, Canada

[76] University of Toronto, Department of Psychiatry, Toronto, Canada

[77] University of Toronto, Institute of Medical Science, Toronto, Canada

[78] University of California San Diego, Department of Psychiatry, San Diego, CA, USA

[79] Florida State University, Department of Psychology, Tallahassee, FL, USA

[80] Michigan State University, Department of Psychology, Lansing, MI, USA

[81] Veterans Affairs Connecticut Healthcare Center, Department of Psychiatry, West Haven, CT, USA

[82] Yale University School of Medicine, Division of Human Genetics, Department of Psychiatry, New Haven, CT, USA

[83] University Medical Center, Department of Psychiatry and Psychotherapy, Mainz, Germany

[84] The Chicago School of Professional Psychology, Washington DC, Department of Clinical Psychology, Washington, DC, USA

[85] Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, Atlanta, GA, USA

[86] King Abdullah University of Science and Technology, BESE Division, Thuwal, Saudi Arabia

[87] University of Lausanne-University Hospital of Lausanne (UNIL-CHUV), Department of Psychiatry, Lausanne, Switzerland

[88] The Hospital for Sick Children, Department of Paediatric Laboratory Medicine, Toronto, Canada

[89] University of North Dakota School of Medicine and Health Sciences, Department of Psychiatry and Behavioral Science, Fargo, ND, USA

[90] HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA

[91] Kobe University Graduate School of Medicine, Department of Psychiatry, Kobe, Japan

[92] Broad Institute, Stanley Center for Psychiatric Research, Cambridge, MA, USA

[93] Massachusetts General Hospital, Analytical and Translational Genetics Unit, Boston, MA, USA

[94] Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Department of Psychiatry, Berlin, Germany

[95] Saint-Petersburg State University, Department of Psychology, Saint-Petersburg, Russian Federation

[96] V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Department of Borderline Disorders and Psychotherapy, Saint-Petersburg, Russian Federation

[97] The Hospital for Sick Children, Department of Genetics and Genomic Biology, Toronto, Canada

[98] University of Toronto, McLaughlin Center, Toronto, Canada

[99] Karolinska Institutet, National Centre for Suicide Research and Prevention of Mental Ill-Health (NASP),

LIME, Stockholm, Sweden
[100] Aarhus University, Centre for Genomics and Personalized Medicine, CGPM, Aarhus, Denmark
[101] Aarhus University, Centre for Integrative Sequencing, iSEQ, Aarhus, Denmark
[102] Aarhus University, Department of Biomedicine, Aarhus, Denmark
[103] Aarhus University, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark
[104] University of California Los Angeles, David Geffen School of Medicine, Los Angeles, LA, USA
[105] University of California Los Angeles, Department of Psychiatry and Biobehavioral Science, Semel Institute for Neuroscience and Human Behavior, Los Angeles, LA, USA
[106] King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, UK
[107] King's College London and South London and Maudsley National Health Service Foundation Trust, National Institute for Health Research Biomedical Research Centre, London, UK
[108] University of Michigan, Population Studies Center, Institute for Social Research, Ann Arbor, MI, USA
[109] University of Michigan, Survery Research Center, Institute for Social Research, Ann Arbor, MI, USA
[110] Curtin University, School of Psychology, Perth, Western Australia, Australia
[111] The University of Western Australia, Division of Paediatrics, Perth, Western Australia, Australia
[112] University Health Network, Centre for Mental Health, Toronto, Canada
[113] University Health Network, Program for Eating Disorders, Toronto, Canada
[114] Aarhus University, National Centre for Register-Based Research, Aarhus, Denmark
[115] University of North Carolina at Chapel Hill, Department of Genetics, Chapel Hill, NC, USA
[116] Umeå University Medical Faculty, Department of Clinical Sciences, Psychiatry, Umeå, Sweden
[117] Diakonhjemmet Hospital, Department of Psychiatric Research, Oslo, Norway
[118] Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
[119] University of Oslo, NORMENT, Institute of Clinical Medicine, Oslo, Norway
[120] University of Adelaide, Discipline of Psychiatry, Adelaide, SA, Australia
[121] Dalhousie University, Department of Psychiatry, Halifax, NS, Canada
[122] National Institute of Mental Health, Klecany, CZ
[123] Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
[124] Karolinska Institutet, Inst of Environmental Medicine, Stockholm, Sweden
[125] Berkshire Healthcare NHS Foundation Trust, Psychiatry, Bracknell, UK
[126] Copenhagen University Hospital, Institute of Biological Psychiatry, Copenhagen Mental Health Services, Copenhagen, Denmark
[127] iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Copenhagen, Denmark
[128] Hospital Universitari Vall d'Hebron, Department of Psychiatry, Barcelona, Spain
[129] Instituto de Salud Carlos III, Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain
[130] University of Barcelona, Department of Genetics, Microbiology & Statistics, Barcelona, Spain
[131] Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction,, Barcelona, Spain
[132] University Medicine Greifswald, Department of Psychiatry and Psychotherapy, Greifswald, Mecklenburg-Vorpommern, Germany
[133] German Centre for Neurodegenerative Diseases (DZNE), Partner Site Rostock/Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
[134] University of Coimbra, Department of Psychiatry, Coimbra, Portugal
[135] University College London, Division of Psychiatry, London, UK
[136] Hospital de Clínicas de Porto Alegre, Laboratory of Developmental Psychiatry, Porto Alegre, RS, Brazil
[137] Universidade Federal do Rio Grande do Sul, Department of Genetics, Porto Alegre, RS, Brazil
[138] University of Melbourne, Department of Psychiatry, Melbourne Medical School, Melbourne, Australia
[139] University of Münster, Department of Psychiatry, Münster, Germany
[140] Assistance Publique - Hôpitaux de Paris, Department of Psychiatry and Addiction Medicine, Paris, France
[141] FondaMental Foundation, Paris Bipolar and TRD Expert Centres, Paris, France

[142] INSERM, UMR-S1144 Team 1 : Biomarkers of relapse and therapeutic response in addiction and mood disorders, Paris, France

[143] Université Paris Cité, Psychiatry, Paris, France

[144] University of Münster, Institute of Epidemiology and Social Medicine, Münster, Nordrhein-Westfalen, Germany

[145] Mayo Clinic, Health Sciences Research, Rochester, MN, USA

[146] State University of New York Downstate Medical Center, Department of Psychiatry and Behavioral Sciences, New York, NY, USA

[147] Max Planck Institute of Psychiatry, Department of Translational Research in Psychiatry, Munich, Germany

[148] University of Michigan, Center for Statistical Genetics and Department of Biostatistics, Ann Arbor, MI, USA

[149] UMC Utrecht Brain Center, Psychiatry, Utrecht, Netherlands

[150] Universitat Autònoma de Barcelona, Department of Psychiatry and Legal Medicine, Barcelona, Spain

[151] University of California San Diego, Department of Psychiatry, La Jolla, CA, USA

[152] University of New South Wales, School of Psychology, Sydney, NSW, Australia

[153] University Hospital, LMU Munich, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany

[154] The University of Queensland, Child Health Research Centre, Brisbane, QLD, Australia

[155] UMC Utrecht Hersencentrum Rudolf Magnus, Department of Psychiatry, Utrecht, Netherlands

[156] University of Granada, Mental Health Unit, Department of Psychiatry, Faculty of Medicine, Granada University Hospital Complex, Granada, Spain

[157] CNRS GDR 3557, Institut de Psychiatrie, Paris, France

[158] GHU Paris Psychiatrie et Neurosciences, Department of Evaluation, Prevention and Therapeutic innovation, Paris, France

[159] Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team Pathophysiology of psychiatric diseases, Paris, France

[160] Research Centre Jülich, Institute of Neuroscience and Medicine (INM-1), Jülich, Germany

[161] University Hospital Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland

[162] University of Basel, Department of Biomedicine, Basel, Switzerland

[163] University of Bonn, School of Medicine & University Hospital Bonn, Institute of Human Genetics, Bonn, Germany

[164] Trinity College Dublin, Neuropsychiatric Genetics Research Group, Dept of Psychiatry and Trinity Translational Medicine Institute, Dublin, Ireland

[165] Cardiff University, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff, UK

[166] University of Southern California, Department of Translational Genomics, Pasadena, CA, USA

[167] Oslo University Hospital, Department of Medical Genetics, Oslo, Norway

[168] University of Bergen, NORMENT, KG Jebsen Centre for Psychosis Research, Department of Clinical Science, Bergen, Norway

[169] Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Department of Genetic Epidemiology in Psychiatry, Mannheim, Germany

[170] University of Marburg, Centre for Human Genetics, Marburg, Germany

[171] Mayo Clinic, Department of Psychiatry & Psychology, Rochester, MN, USA

[172] NorthShore University HealthSystem, Department of Psychiatry and Behavioral Sciences, Evanston, IL, USA

[173] University of Chicago, Department of Psychiatry and Behavioral Neuroscience, Chicago, IL, USA

[174] Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria

[175] University of Munich, Department of Psychiatry, Munich, Germany

[176] University of New South Wales, School of Psychiatry, Sydney, NSW, Australia

[177] Hospital de Clínicas de Porto Alegre, ADHD Outpatient Program, Adult Division, Porto Alegre, RS, Brazil

[178] Universidade Federal do Rio Grande do Sul, Department of Psychiatry, Porto Alegre, RS, Brazil

[179] Alexandru Obregia Clinical Psychiatric Hospital, Biometric Psychiatric Genetics Research Unit, Bucharest, Romania

[180] University of Granada, Department of Psychiatry, Faculty of Medicine and Biomedical Research

Centre (CIBM), Granada, Spain
[181] University Regional Hospital. Biomedicine Institute (IBIMA), Mental Health Department, Málaga, Spain
[182] Kaiser Permanente Northern California, Psychiatry, San Francisco, CA, USA
[183] Poznan University of Medical Sciences, Psychiatric Genetics, Department of Psychiatry, Poznan, Poland
[184] Max Planck Institute of Psychiatry, Munich, Germany
[185] University of Worcester, Department of Psychological Medicine, Worcester, UK
[186] University of Gothenburg, Department of Psychiatry and Neuroscience, Gothenburg, Sweden
[187] UMC Utrecht Brain Center Rudolf Magnus, Psychiatry, Utrecht, Netherlands
[188] University of California San Diego, Institute for Genomic Medicine, La Jolla, CA, USA
[189] University of Toronto, Department of Psychiatry, Toronto, ON, Canada
[190] Harvard TH Chan School of Public Health, Department of Epidemiology, Boston, MA, USA
[191] Massachusetts General Hospital, Department of Psychiatry, Boston, MA, USA
[192] Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
[193] University of Gothenburg, Institute of Neuroscience and Physiology, Gothenburg, Sweden
[194] North East London NHS Foundation Trust, Psychiatry, Ilford, UK
[195] Univ Paris Est Créteil, INSERM, AP-HP, IMRB, Translational Neuropsychiatry, DMU IMPACT, FHU ADAPT, Fondation FondaMental, Créteil, France
[196] INSERM, Paris, France
[197] Université Paris Est, Faculté de Médecine, Créteil, France
[198] Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit, Boston, MA, USA
[199] Stanford University, Psychiatry & Behavioral Sciences, Stanford, CA, USA
[200] Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Research, Cambridge, MA, USA
[201] Massachusetts General Hospital, Analytical and Translational Genetics Unit, Cambridge, MA, USA
[202] M. Sklodowska-Curie Cancer Center and Institute of Oncology, Cancer Epidemiology and Prevention, Warsaw, Poland
[203] Lindner Center of HOPE, Research Institute, Mason, OH, USA
[204] Columbia University College of Physicians and Surgeons, Psychiatry, New York, NY, USA
[205] Queensland University of Technology, School of Psychology and Counseling, Brisbane, QLD, Australia
[206] The University of Queensland, Queensland Brain Institute, Brisbane, QLD, Australia
[207] University of Oslo, Institute of Clinical Medicine, Division of Mental Health and Addiction, Oslo, Norway
[208] Amsterdam UMC, Vrije Universiteit and GGZ inGeest, Department of Psychiatry, Amsterdam, Netherlands
[209] University of Granada, Department of Nursing, Faculty of Health Sciences and Biomedical Research Centre (CIBM), Granada, Spain
[210] Norwegian University of Science and Technology - NTNU, Mental Health, Faculty of Medicine and Health Sciences, Trondheim, Norway
[211] St Olavs University Hospital, Psychiatry, Trondheim, Norway
[212] Aarhus University, Centre for Integrated Register-based Research, Aarhus, Denmark
[213] Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
[214] University of Liverpool, Liverpool, UK
[215] University of Pittsburgh, Psychiatry and Human Genetics, Pittsburgh, PA, USA
[216] Erasmus University Medical Center, Psychiatry, Rotterdam, Netherlands
[217] Rutgers University, RWJMS,NJMS,UBHC, Piscataway, NJ, USA
[218] Rutgers University, RWJMS,NJMS, Piscataway, NJ, USA
[219] Amsterdam UMC, Vrije Universiteit, Department of Psychiatry and Amsterdam Neuroscience, Amsterdam, Netherlands
[220] Johns Hopkins University School of Medicine, Psychiatry, Baltimore, MD, USA
[221] BioMarin Pharmaceuticals, Genetics, London, UK
[222] University of Oxford, St Edmund Hall, Oxford, UK
[223] University of Oxford, Department of Psychiatry, Oxford, UK
[224] University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt, Germany
[225] Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Department of

Genetic Epidemiology in Psychiatry, Mannheim, Baden-Württemberg, Germany

[226] University of Granada, Department of Biochemistry and Molecular Biology II and Institute of Neurosciences, Biomedical Research Centre (CIBM), Granada, Spain

[227] Harvard TH Chan School of Public Health, Department of Environmental Health, Boston, MA, USA

[228] McGill University, Faculty of Medicine, Department of Neurology and Neurosurgery, Montreal, QC, Canada

[229] Montreal Neurological Institute and Hospital, Montreal, QC, Canada

[230] Instituto de Ciencias Biomedicas Universidade de Sao Paulo, Department of Physiology and Biophysics, São Paulo, SP, Brazil

[231] Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD, USA

[232] National Institute of Mental Health, Human Genetics Branch, Intramural Research Program, Bethesda, MD, USA

[233] University Medical Center Göttingen, Department of Psychiatry and Psychotherapy, Göttingen, Germany

[234] University of Bologna, Department of Biomedical and NeuroMotor Sciences, Bologna, Italy

[235] National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA

[236] Kaiser Permanente Washington, Behavioral Health Services, Seattle, WA, USA

[237] Icahn School of Medicine at Mount Sinai, Department of Neuroscience, New York, NY, USA

[238] Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Boston, MA, USA

[239] King's College London, Institute of Psychology, Psychiatry & Neuroscience, London, UK

[240] Baylor College of Medicine, Houston, Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX, USA

[241] IRCCS Santa Lucia Foundation, Rome, Laboratory of Neuropsychiatry, Rome, Italy

[242] Nofer Institute of Occupational Medicine, Department of Environmental Epidemiology, Lodz, Poland

[243] University of California, San Diego, Center for Behavioral Genomics, Department of Psychiatry, La Jolla, CA, USA

[244] McGill University, Department of Psychiatry, Montreal, QC, Canada

[245] Centre for Addiction and Mental Health, Molecular Brain Science, Toronto, ON, Canada

[246] University Medicine Greifswald, Institute for Community Medicine, Greifswald, Mecklenburg-Vorpommern, Germany

[247] Columbia University College of Physicians and Surgeons, New York, NY, USA

[248] New York State Psychiatric Institute, Division of Translational Epidemiology, New York, NY, USA

[249] Stanford University, Department of Psychiatry and Behavioral Sciences, Stanford, CA, USA

[250] University of Toronto, Institute of Medical Science, Toronto, ON, Canada

[251] Centre for Addiction and Mental Health, Molecular Brain Science, Campbell Family Mental Health Research Institute, Toronto, ON, Canada

[252] University of Toronto, Laboratory Medicine and Pathobiology, Toronto, ON, Canada

[253] iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark

[254] Australian National University, Center of Mental Health Research, Canberra, Australia

[255] Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, USA

[256] Mental Health Centre Copenhagen, Danish Research Institute for Suicide Prevention, Copenhagen, Denmark

[257] Broad Institute, Program in Medical and Population Genetics, Cambridge, MA, USA

[258] University of Tartu, Estonian Genome Center, Institute of Genomics, Tartu, Estonia

[259] SUNY Upstate Medical University, Department of Psychiatry and Behavioral Sciences, Syracuse, NY, USA

[260] Statens Serum Institut, Center for Neonatal Screening, Department for Congenital Disorders, Copenhagen, Denmark

[261] National Taiwan University Hospital and College of Medicine, Department of Psychiatry, Taipei, Taiwan

[262] King's College London, Department of Medical & Molecular Genetics, London, UK

[263] Janssen Research & Development, LLC, Neuroscience, Titusville, NJ, USA

[264] Aarhus University Hospital, Risskov, Psychosis Research Unit, Aarhus, Denmark

[265] Copenhagen University Hospital, Mental Health Center Copenhagen, Copenhagen, Denmark

[266] QIMR Berghofer Medical Research Institute, Department of Population Health, Brisbane, QLD, Australia
[267] University of Edinburgh, Institute for Genetics and Molecular Medicine, Edinburgh, UK
[268] University of Edinburgh, Centre for Clinical Brain Sciences, Edinburgh, UK
[269] Regeneron Genetics Center, Analytical Genetics and Data Science, Tarrytown, NY, USA
[270] University of California San Diego, Department of Psychiatry and School of Public Health, La Jolla, CA, USA
[271] University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark
[272] University of Copenhagen, Lundbeck Foundation GeoGenetics Centre, GLOBE Institute,, Copenhagen, Denmark
[273] University of Iowa, Department of Psychiatry, Iowa City, IA, USA
[274] University of Utah School of Medicine, Biomedical Informatics, Salt Lake City, UT, USA
[275] Durham Veterans Affairs Health Care System, VISN 6 Mid-Atlantic Mental Illness Research, Education, and Clinical Center, Durham, NC, USA
[276] Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, Durham, NC, USA
[277] Vanderbilt University Medical Center, Department of Biomedical Informatics, Nashville, TN, USA
[278] Vanderbilt University Medical Center, Department of Psychiatry and Behavioral Sciences, Nashville, TN, USA

Previous presentation: Society of Biological Psychiatry, 2022, New Orleans, Louisiana, USA.

Address for reprint: Corresponding author, Anna R. Docherty, Department of Psychiatry, University of Utah School of Medicine, 501 Chipeta Way, Salt Lake City, Utah 84110, USA, tel. +1 763 516 7367. Email: anna.docherty@utah.edu.

Disclosures: Dr. Qingqin Li is employed by Janssen Pharmaceuticals. Dr. Eli Stahl is a full-time employee of the Regeneron Genetics Center, a subsidiary of Regeneron Pharmaceuticals Inc. All other authors have no financial relationships with commercial interests.

Abstract

Objective: Suicidal behavior is heritable and a major cause of death worldwide. Two large-scale genome-wide association studies (GWAS) recently discovered and cross-validated genome-wide significant (GWS) loci for suicide attempt (SA). The current study leveraged the genetic cohorts from both studies to conduct the largest GWAS meta-analysis of SA to date. Multi-ancestry and ancestry-specific meta-analyses were conducted within African American, East Asian, and European ancestries.

Methods: This study was comprised of 22 cohorts, including 43,871 SA cases and 915,025 ancestry-matched controls. Analytical methods across multi-ancestry and ancestrally-specific groupings included inverse variance-weighted fixed effects meta-analyses, followed by gene, gene-set, tissue-set, drug-target enrichment, summary-data-based Mendelian Randomization with brain eQTL data, and phenome-wide genetic correlation and genetic causal proportion analyses.

Results: Multi-ancestry and European GWAS meta-analyses identified 12 risk loci at $p<5 \times 10^{-8}$. These loci were mostly intergenic and implicated *DRD2, SLC6A9, FURIN, NLGN1, SOX5, PDE4B,* and *CACNG2*. The multi-ancestry SNP-based heritability estimate of SA was 5.7% on the liability scale (SE=0.003, $p = 5.70 \times 10^{-80}$). Significant brain tissue gene expression and drug set enrichment was observed, along with shared genetic variation of SA with ADHD, smoking, and risk tolerance after conditioning SA on both major depressive disorder and post-traumatic stress disorder. Genetic causal proportion analyses implicated genetic risk for specific health factors.

Conclusions: This multi-ancestry analysis of suicide attempt identified several loci contributing to risk, and establishes significant shared genetic covariation with relevant clinical phenotypes that is not better accounted for by genetic risk for major depressive disorder or post-traumatic stress disorder. These findings provide insight into genetic factors associated with suicide attempt across ancestries, in veteran and civilian populations, and in attempt versus death.

Introduction

Suicide was the fourth leading cause of death among 15–29-year-olds in 2019, accounting for more than 700,000 deaths worldwide (1). Suicide attempts—defined as self-injurious behaviors with an intent to die—are even more common (2-4). Suicide attempts are strongly associated with psychiatric conditions, poor quality of life, traumatic experiences, and social and economic burden (1), and are the single strongest predictor of future suicide death (5).

Heritability estimates for suicidal thoughts and behaviors from twin and family studies range from 30-55% (6), and recent large-scale genome-wide association studies (GWAS) have yielded promising and replicable results. The International Suicide Genetics Consortium (ISGC; total N=549,743; 29,782 cases) identified two loci reaching genome-wide significance for suicide attempt in European ancestry on chromosomes 6 (index SNP rs71557378, $p = 1.97 \times 10^{-8}$) and 7 (index SNP rs62474683, $p = 1.91 \times 10^{-10}$) (7). The intergenic locus on chromosome 7 remained significant after conditioning on psychiatric disorders, and was independently replicated ($p = 3.27 \times 10^{-3}$) (8) within the Million Veteran Program (MVP) cohort (9).

The MVP cohort reflects the largest genetic study of suicide attempt among military veterans to date (total N=409,153; 14,089 cases). This analysis resulted in two genome-wide significant multi-ancestry loci on chromosomes 20 (index SNP rs56817213, $p = 3.64 \times 10^{-9}$) and 1 (index SNP rs72730526, $p = 3.69 \times 10^{-8}$) (8). A top signal identified at the *Dopamine Receptor D2* locus ($p = 1.77 \times 10^{-7}$) also showed moderate association in the ISGC GWAS ($p = 7.97 \times 10^{-4}$) (7).

These studies established the complexity of the common variant genetic architecture of suicide attempt, and demonstrate the critical role of sample size for discovering novel, replicable risk loci for complex phenotypes through GWAS (10). Together, these GWAS suggested that larger studies will identify additional genomic risk loci and refine genetic risk metrics.

The objective of the current study was to conduct a meta-analysis of the ISGC and MVP studies (total N=958,896; 43,871 suicide attempt and suicide death cases). Moreover, there is considerable need to increase the diversity and generalizability of GWAS data (11). Combining all ISGC and MVP cohorts allowed for the largest ancestry-specific GWAS meta-analyses in European, African American and East Asian ancestral cohorts to date, and to test for gene set enrichment and functional follow-up specific to these ancestral populations.

Methods

GWAS Cohorts and Phenotype Ascertainment

The International Suicide Genetics Consortium (ISGC) Cohort

The ISGC analyses included 29,782 suicide attempt (SA) and/or suicide death (SD) cases and 519,961 controls from 18 cohorts (15 SA, 2 SD, and 1 both), 12 of which were ascertained clinically for the purpose of studying psychiatric disorders. Details about the specific cohorts have been described previously (7) and cohort references and ascertainment methods are summarized in Supplementary Table S1. Twelve SA cohorts ascertained information on SA via in-person structured psychiatric interviews conducted by trained clinicians/researchers, two SA cohorts used self-report, and two SA cohorts used ICD codes or hospital records. All interviews and self-report items asked explicitly about SA rather than self-harm (which would also include

non-suicidal self-injury). ICD codes were coupled with information from emergency room settings, reason for contact information, and attempt methods that were mined from physician notes, in order to maximize evidence that suicidal intent was present. For the cohorts using interviews or self-report to ascertain SA information, the SA was non-fatal. An additional two cohorts explicitly ascertained cases of suicide death (SD). The majority of SD cases were ascertained from the Utah Office of the Medical Examiner (Utah n = 4,692). In these cases, suicide cause-of-death determination results from a detailed investigation of the scene of the death and circumstances of death, determination of medical conditions by full autopsy, review of medical and other public records concerning the case, interviews with survivors, and standard toxicology workups (12). Suicide determination is traditionally conservative due to its impact on surviving relatives. In the 746 suicide deaths from Japan, autopsies on suicides were performed and cause of death was determined through discussion with the Medical Examiner's Office and the Division of Legal Medicine in the Kobe University Graduate School of Medicine. The Columbia University cohort of both SA and SD included 317 suicide deaths that were determined by psychological autopsy and the coroner or medical examiner. A psychological autopsy is a method of determining the psychological factors that may have contributed to a death. It is typically used in cases of suspected suicide or sudden, unexpected death, and involves interviewing family members, friends, and other people who knew the deceased, as well as reviewing medical records and other relevant documents.

The Million Veteran Program (MVP) Cohort

MVP recruitment and study procedures have been described previously (8) and included veterans providing a blood sample, consenting to genetic analyses and the linking of one's genetic information to the VA's electronic health records (EHR), and completing two optional surveys (9, 13). SA was defined as an act of deliberate self-harm with the intent to cause death that occurred at any point over the lifetime. Briefly, cases were defined as veterans with a documented history of SA in the EHR (N=14,089) and controls were defined as veterans with no documented history of suicidal thoughts or behaviors in the EHR (N=395,064). VA EHR sources were utilized to create a SA phenotype using: (a) diagnostic codes for intentional self-harm; (b) suicidal behavior reports from the VA's Suicide Prevention Applications Network (SPAN) database; and (c) mental health survey responses from the VA's Mental Health Assistant database indicating a history of attempting suicide. Veterans who had a history of suicidal ideation but no SA were excluded from analysis. For all ISGC and MVP cohorts, it remains undetermined which individuals with SA may have later died by suicide. Details of sample sizes by genetic ancestry for the ISGC and MVP cohorts are presented in Table 1.

Genotyping, quality control, and imputation

Details of genotyping, quality control (QC), and imputation for the ISGC and MVP data sets have been described previously (7, 8). In the ISGC analyses, genotyping was performed locally by each of the research teams using comparable procedures[8] (details per cohort are available in the Table S1). Standard parameters were used to retain individuals and SNPs after quality control for missingness, relatedness, and Hardy-Weinberg equilibrium. Genetic ancestry was defined by the contributing cohorts, and we include all ascertainment, QC, and analysis details of the ISGC and MVP cohorts in Supplemental Table 1. Imputation was performed using the largest available ancestrally matched reference panels, either from 1000 Genomes or the Haplotype Reference Consortium. We confirmed the comparability of imputation across the cohorts by comparing the final set of SNPs in the meta-analysis, including the number of cohorts in which they were present, and the INFO scores across cohorts and within ancestry groups. Sample overlap and/or cryptic relatedness across cohorts was assessed and corrected

for using the meta-analytic tools described below. Eight of the cohorts had high control:case ratios (using an arbitrary cut-off of >15:1). In these cases, the LD Score regression (14) (LDSC) attenuation ratio statistics were examined for evidence of population stratification or uncontrolled type 1 error in the cohort. For any evidence of inflation, the intercept was used to adjust the SE of the summary statistics.

GWAS meta-analysis of suicide attempt

For both the ISGC and MVP cohorts, the initial GWAS analysis was conducted within genetic ancestral groups. For the ISGC meta-analysis, GWAS were conducted within study and genetic ancestral group, covarying for at least 10 principal components of genetic ancestry, genomic relatedness matrices or factors capturing site of recruitment or genotyping batch, as required (7). For the MVP cohort, ancestry was defined for four mutually exclusive ancestral groups utilizing a previously defined approach harmonizing genetic ancestry and self-identified ancestry (HARE) (15). Subsequent MVP GWAS analyses were performed within ancestral group using PLINK2 (16), covarying for genetic ancestry principal components, age, and sex.

A multi-ancestry meta-analysis of SA GWAS summary statistics was conducted using an inverse variance-weighted fixed effects model (standard error) in METAL (17), assuming shared risk effects across ancestries. SNPs with a mean weighted minor allele frequency of <1%, mean weighted imputation INFO score <0.6 or SNPs present in <80% of the total effective sample size were removed to ensure adequate statistical power at every variant included. Ancestry-specific GWAS meta-analyses were conducted in European, African American, and East Asian ancestry cohorts using the same procedures. Inflation of test statistics due to polygenicity or cryptic relatedness were assessed using the LDSC attenuation ratio ((LDSC intercept - 1)/(mean of association chi-square statistics - 1)). Resulting genome-wide significant (GWS) loci were defined as those with $p<5\times10^{-8}$ with LD $r^2>0.1$, within a 3,000 kb window, based on the structure of the Haplotype Reference Consortium (HRC) EUR reference panel for the multi-ancestry meta-analysis, or the HRC ancestry-appropriate reference panel otherwise. GWS loci for SA were examined for heterogeneity across cohorts via the I^2 inconsistency metric and forest plots.

Estimation of heritability and genetic association with other disorders

LDSC (17) or cov-LDSC (18) methods were used to estimate the phenotypic variance in SA explained by common SNPs (SNP-based heritability, h^2_{SNP}) from the GWAS meta-analysis summary statistics. Covariate-adjusted LD scores from Pan UK BioBank (Pan UKBB, https://pan.ukbb.broadinstitute.org) were used for analyses containing ancestry admixtures (AA and LAT). The attenuation ratio for AA was high using UKBB AFR, and it was observed that unadjusted AA LD scores from gnomAD v2.1.1 provided a reduced ratio for this African-American GWAS meta-analysis. h^2_{SNP} was calculated on the liability scale assuming a lifetime prevalence of SA in the general population of 2% (middle of the range reported worldwide) (19). The default script of LDSC was used to exclude SNPs with MAF<1% and INFO<0.9 and also to restrict variants to the list of approximately 1.2 million HAPMAP SNPs that are typically well-imputed across datasets. h^2 estimates remained stable across >2% and >5% MAF thresholds. The genetic correlation attributable to genome-wide SNPs (r_G) was estimated between the ancestral groups using the Popcorn package (20), and with a range of psychiatric disorders in EUR using LDSC and the largest available discovery GWAS meta-analysis summary statistics. The latter analyses were confined to EUR ancestry for consistency with the discovery summary data. Tests were Bonferroni-corrected, adjusting for up to 18 phenotypes hypothesized to be associated with SA. Traits were selected based on previous epidemiological association and/or

previous evidence of genetic association in LD Hub (21). Previous LD Hub analyses in ISGC were pre-categorized manually into risk factor groups relevant to SA (5, 22, 23): autoimmune disease, neurologic disease, heart disease, hypertension, diabetes, kidney disease, cancer, alcohol use, smoking, pain, psychiatric, sleep, life stressors, socioeconomic, and education/cognition. r_G of SA in ISGC and MVP in this study were calculated using LDSC, and references for the discovery GWAS are listed in Table S2. Differences in r_G across other phenotypes using EUR GWAS meta-analyses were tested as a deviation from 0, using the block jackknife method implemented in LDSC (24). To examine phenome-wide partial genetic causality, the Complex-Traits Genetics Virtual Lab (CTG-VL) (25) was used to conduct FDR-corrected Genetic Causal Proportion (GCP) analyses on the EUR summary data.

Conditioning suicide attempt on major depressive disorder and PTSD

The EUR GWAS SA meta-analysis was conditioned on genetic risks for major depressive disorder (MDD) (26) and post-traumatic stress disorder (PTSD) (27), because both are highly co-morbid with SA, and because PTSD is particularly prevalent within military veteran populations (i.e., MVP). The results of the meta-analysis were conditioned on MDD and PTSD to examine genetic associations both shared with and unique to suicide risk. Conditioning was conducted using mtCOJO (multi-trait-based COnditional & JOint analysis using GWAS summary data) (28), implemented in GCTA software (29). mtCOJO estimates the effect size of a SNP on an outcome trait (e.g., SA) conditioned on exposure trait(s) (e.g., MDD). GWS SNPs for the exposure are used as instruments to estimate the effect of the exposure on the outcome, and this effect is used to perform genome-wide conditioning, yielding conditioned effect sizes and p-values for the outcome trait. The EUR-only SA GWAS summary statistics were used as the outcome trait, because mtCOJO requires GWAS summary statistics for the exposure trait, which were derived from EUR ancestry discovery GWAS. To select independent SNPs as instruments, we selected those more than 1 megabase (Mb) apart or with an LD $r^2<0.05$ based on the 1000 Genomes Project Phase 3 EUR reference panel (30). mtCOJO is robust to sample overlap between the GWAS of the exposure and outcome. In this analysis, statistical power to detect genetic associations at individual SNPs was reduced relative to the unconditioned analysis by the additional model parameters, but the genetic correlations using the conditioned summary statistics provide valuable insights into the relevant risk factors for SA over and above those related to MDD and PTSD.

Gene, gene pathway, and tissue enrichment analyses

Enrichment analyses of the GWAS results were performed to probe genes, biological pathways, and tissues implicated in SA, using the multi-ancestry and ancestry-specific GWAS results. *P*-values quantifying the degree of association of genes and gene sets with SA were calculated using MAGMA v1.08 (31), implemented in FUMA v1.3.7 (32). Input SNPs were mapped to 18,627 protein-coding genes. Genome-wide significance was defined at $p = 0.05/18,627 = 2.68 \times 10^{-6}$. Curated gene sets including at least 10 genes from MSigDB V7.0 were tested for association with SA. Competitive gene-set tests were conducted to correct for gene size, variant density and LD within and between genes. Tissue-set enrichment analyses were also performed using MAGMA implemented in FUMA, to test for enrichment of association signal in genes expressed in 54 tissue types from GTEx V8 (33) (Bonferroni-corrected *p*-value threshold = 9.26×10^{-4}).

Drug target enrichment analyses

Additional gene-set enrichment analyses, of both the multi-ancestry and EUR ancestry GWAS meta-analysis results, were performed restricted to genes targeted by drugs, in order to investigate putative relationships of suicide attempt with specific drug types. These analyses do not identify causal relationships, but may implicate genes relevant to pharmacotherapy. This approach has been described previously (34). Gene-level and gene-set analyses were performed in MAGMA v1.08. Gene boundaries were defined using build 37 reference data from the NCBI, available on the MAGMA website (https://ctg.cncr.nl/software/magma), extended 35kb upstream and 10kb downstream to increase the likelihood of including regulatory regions outside of the transcribed region. Gene-level association statistics were defined as the aggregate of the mean and the lowest variant-level *p*-value within the gene boundary, converted to a *Z*-value. Gene sets were defined comprising the targets of each drug in the Drug-Gene Interaction database DGIdb v.2 (35) and in the Psychoactive Drug Screening Ki Database, both downloaded in June 2016 (34). Analyses were performed using competitive gene-set analyses in MAGMA.

Results from the drug-set analysis were then grouped according to the Anatomical Therapeutic Chemical class of the drug (34). Only drug classes containing at least 10 valid drug gene sets within them were analyzed, and drug-class analysis was performed using enrichment curves. All drug gene sets were ranked by their association in the drug-set analysis, and then for a given drug class, an enrichment curve was drawn scoring a "hit" if the drug gene set was within the class, or a "miss" if it was outside of the class. The area under the curve was calculated, and a *p*-value for this calculated as the Wilcoxon Mann-Whitney test comparing drug gene sets within the class to drug gene sets outside of the class (34). A Bonferroni-corrected significance threshold of $p < 5.79 \times 10^{-5}$ and $p < 4.35 \times 10^{-4}$ were used for the drug-set and the drug-class analysis, respectively, accounting for 863 drug-sets and 115 drug classes.

Summary data-based Mendelian randomization

Summary data-based Mendelian randomization (SMR) (v1.03) (36, 37) was applied to detect GWAS signals that co-localize with expression quantitative trait loci (eQTLs), in order to investigate putative causal relationships between SNPs and SA via gene expression. SMR was performed using eQTL summary statistics from the MetaBrain consortium (38), a cortex-derived eQTL dataset consisting of 2,970 EUR-cortex samples. The analysis was conducted using the EUR-only GWAS meta-analysis results, for consistency with the eQTL data. Brain eQTL data from comparable sample sizes in other ancestral groups is not currently available. SMR analysis was limited to transcripts with at least one significant *cis*-eQTL ($p < 5 \times 10^{-8}$) in the dataset (8,753 in MetaBrain). The Bonferroni-corrected significance threshold for the SMR analysis was $p < 5.71 \times 10^{-6}$ and the significance threshold for the HEIDI test (HEterogeneity In Dependent Instruments) (39) was $p \geq 0.01$. A non-significant HEIDI test suggests a direct causal role, rather than a pleiotropic effect, of the SA-associated SNPs on gene expression.

Polygenic risk scoring

Polygenic risk scores (PRS) for SA were tested for association with SA versus controls in six target cohorts: PGC MDD, BIP and SCZ (all EUR ancestry), CONVERGE (EAS ancestry), and Yale-Penn and Grady Trauma Project cohorts (both AA ancestry). The SA GWAS meta-analysis was repeated, excluding each cohort in turn, to create independent discovery datasets. PRS were generated using PRS-CS (39), which uses a Bayesian regression framework to place continuous shrinkage priors on the effect sizes of SNPs in the PRS, adaptive to the strength of their association signal in the discovery GWAS and the LD structure from an external reference

panel. The 1000 Genomes EUR, EAS or African reference panels (30) were used to estimate LD between SNPs, as appropriate for each target cohort. PLINK 1.9 (16) was used to weight SNPs by their effect sizes calculated using PRS-CS and sum all SNPs into PRS for each individual in the target cohorts. PRS were tested for association with case versus control status in the target cohort using a logistic regression model including covariates as per the GWAS. The amount of phenotypic variance explained by the PRS (R^2) was calculated on the liability scale, assuming a lifetime prevalence of SA in the general population of 2% (19). The Bonferroni-corrected significance threshold adjusting for six tests was P<0.008.

Results

Significant shared genetic architecture of SA between civilian (ISGC) and military populations (MVP)

The multi-ancestry GWAS included 43,871 cases and 915,025 controls from 22 cohorts (Table 1). Cohort ancestry was defined by contributing site. Cases were predominantly of European ancestries (EUR, 81%), with 11% of admixed African ancestries (AA), 5% of East Asian ancestries (EAS), and 3% of Latin American ancestries (LAT). Case definition was lifetime SA, with ~13% of all cases having died by suicide. Only one major ancestral group (LAT) was limited to a single cohort and thus not subject to ancestry-specific meta-analysis; all others were included in ancestry-specific meta-analyses. Additional information on study characteristics and ascertainment methods is presented in Supplementary Table S1.

Cohorts across ISGC and MVP differed with respect to ascertainment with ISGC being largely civilian and MVP being military (Table 1a). However, examination of the genetic correlation of EUR GWAS meta-analyses for ISGC and MVP ($r_G = 0.81$, SE = 0.091, $p = 2.85 \times 10^{-19}$) indicated consistency of common-variant genetic architecture across meta-analyses. Results from both fixed and meta-regression models were comparable in the multi-ancestry GWAS meta-analysis (all GWS effect size correlations >.99) indicating that ancestry and cohort ascertainment were unlikely to confound observed genetic effects (Table 1b).

GWAS meta-analysis of SA across and within ancestries identified 12 GWS loci

The multi-ancestry GWAS meta-analysis identified eight genome-wide significant (GWS) loci (P<5x10^{-8}) (Figure 1). The h^2_{SNP} of SA was significant at 5.7% (SE=0.003, $p = 5.70 \times 10^{-80}$) on the liability scale assuming an SA population prevalence of 2%. The cov-LDSC intercept was 1.04 (SE=0.01, $p = 1.59 \times 10^{-5}$) and the attenuation ratio was 0.13 (SE=0.03), indicating that the majority of inflation of GWAS test statistics is likely due to polygenicity (Supplementary Figure S1).

The locus most strongly associated with SA was in an intergenic region on chromosome 7 (index SNP rs62474683, OR A allele = 1.05 [1.04-1.07], $p = 8.72 \times 10^{-12}$, frequency in cases = 0.57, frequency in controls = 0.56, Forest plot Figure S2). At other GWS loci, index SNPs were intronic in the *SLC6A9, DRD2, HS6ST3* and *FURIN* genes (Table 2; additional summary data of all GWS loci are provided in Table S1b). On chromosome 3, GWS SNPs localized around the 5' untranslated region of the *NLGN1* gene. There was no evidence of heterogeneity of effects across cohorts for any GWS locus according to I^2 heterogeneity indices (Table S1b). Forest plots for GWS loci are included in Figures S2-S9.

The EUR GWAS meta-analysis h^2_{SNP} was estimated at 7.0% (SE=0.004) and identified four additional GWS loci (Table 2, Figure S10, Forest plots Figures S11-14), composed of mostly intergenic index SNPs. The nearest genes were *PDE4B, OTX2-AS1, CACNG2*, and one locus was in the major histocompatibility complex (MHC). GWAS meta-analyses in AA (h^2_{SNP} = 9.8%, SE=0.02) and EAS (h^2_{SNP} = 9.8%, SE=0.05) ancestries produced no GWS loci. The LAT SA h^2_{SNP} (based on the MVP cohort) was estimated at 10.0% (SE=0.07). Regional plots of the 12 GWS risk loci across all meta-analyses are presented in Supplementary Figures S15-S26. Mapped genes from the top loci in multi-ancestry and ancestry-specific meta-analyses are presented in Supplementary Tables S3-S6.

Genetic correlations of SA across ancestry GWAS

The genetic correlations of SA across each of the ancestral groupings were attenuated, with estimated r_Gs(SE) between 0.064(0.574) (EAS with LAT) and 0.997(.537) (EUR with LAT) Popcorn r_G results can be found in Table S7. Individual cohort GWAS were variably powered to estimate genetic correlation estimates with the other cohorts. LDSC estimates across all individual GWAS are presented in Table S8, though cov-LDSC h^2_{SNP} and Popcorn r_Gs in Table S7 are the preferred sources for statistics involving ancestry admixtures.

SA GWS loci are enriched for brain-expressed genes and overlap with previous genetic associations to known risk factors

Significant signal enrichment was observed in genes expressed in pituitary gland and brain tissues, based on the multi-ancestry GWAS (Table S9). Significant gene expression in brain was also observed in the EUR analysis (Table S10). Tissue-set enrichment analyses and corresponding GTEx gene expression heatmaps for all of the multi- and ancestry-specific GWAS are provided in Tables S9-S12 and Figures S31-S34.

Several GWS genes were identified in MAGMA analyses of the multi-ancestry and EUR meta-analyses (Table S13; enrichment of SA signal with genes and gene sets across all meta-analyses are presented in Supplementary Tables S13-S14). MAGMA gene-based tests of the GWAS meta-analyses, with GWS results, are presented in Manhattan plots and QQ-plots in Figures S27-S30. EAS and AA *p*-value thresholds for inclusion of GWAS variants in follow-up analysis were relaxed to $p < 1x10^{-5}$ and $1x10^{-6}$, respectively, in order to explore gene-based tests of top ancestry-specific GWAS variants. Top genes implicated in the EAS analysis included *C11orf87*, *MYO1C*, and *FAXC*, and top genes implicated in the AA analysis included *CNTNAP2*, *IGF2R*, *MAN1B1*, and *SLC22A1*. Neither set of genes was significantly associated with any pathway or tissue enrichment.

Gene-set analyses from the multi-ancestry and EUR GWAS identified 521 significant gene sets (31 and 488, respectively), spanning multiple domains, including epigenetics, gene regulation and transcription, cellular response to stress, DNA repair, and immunologic signatures (Table S14). The 31 multi-ancestry pathways included schizophrenia and autism gene sets, containing protein-coding genes such as *FURIN, FES,* and *DRD2,* mapped from GWS loci. Most of the 488 EUR pathways were due to overlap with a small group of 35 histone-coding genes.

Significant proportions of overlapping genes in GWAS Catalog (40) gene sets were observed for both multi-ancestry and EUR meta-analyses (Figures S35-S36). The 12 GWS loci from the multi-ancestry and EUR GWAS meta-analyses were tagged in several GWAS including cognition, smoking, insomnia, and risky behavior. Six of the 12 risk loci had *p*-values < 0.005 for the "*Suicide or Other Intentional Self-Harm*" analysis in FinnGen. A comprehensive list of results

of SNP associations from the GWAS Catalog is presented in Table S15. Examination of the pheWAS results ($p < 0.005$) across UK Biobank, FinnGen and the GWAS Catalog resulted in the identification of several psychiatric, weight/BMI- and immune-related traits (Table S16).

Two loci implicated specific genes, *FES* and *TIAF1*, that were significantly associated with SA in SMR analyses and passed the HEIDI test. SMR results suggested that SA risk may be mediated by an increased expression of *FES* (previously implicated in cross-ancestry schizophrenia(41)) and decreased expression of *TIAF1* in cortex (Table S17).

Significant overlap of SA GWS loci and targets of antipsychotics and antidepressants

Drug target enrichment results suggested that SA risk is most associated with the targets of antipsychotic and antidepressant drug classes. In the multi-ancestry gene-set analysis of the targets of drug classes defined by their Anatomical Therapeutic Chemical (ATC) classes(34), there was significant enrichment in the targets of four drug classes: *Antipsychotics, Psychoanaleptics*, which includes individually significant *Antidepressants* and its subclass *Other Antidepressants* (Table S18). The class of *Other Antidepressants* includes those not classified as selective serotonin reuptake inhibitors, monoamine oxidase inhibitors or monoamine reuptake inhibitors.

In the EUR analysis, there was significant enrichment in the targets of just three drug classes, including *Antipsychotics*, the broad class of *Psycholeptics* (drugs with a calming effect on behavior), and the class *Cytotoxic Antibiotics and Related Substances* (Table S19). Only one drug, the insecticide cyfluthrin, was significantly enriched when grouping genes targeted by individual drugs (from the Drug-Gene Interaction Database DGIdb v.2 and the Psychoactive Drug Screening Ki Database) and this was only observed in the EUR GWAS results (see Tables S20 and S21 for multi-ancestry and EUR results).

Significant genetic correlation of SA with known non-psychiatric risk factors minimally affected after conditioning on MDD and PTSD

The out-of-sample polygenic risk analyses based on the new ISGC+MVP discovery GWAS meta-analysis statistics resulted in higher R^2 estimates than were observed in ISGC1, particularly for AA (maximum variance explained $R^2 = 0.66\%$, $p = 0.01$, and a maximum increase of 146%) and EAS ($R^2 = 0.34\%$, $p = 8.1 \times 10^{-6}$, a 36% increase. EUR maximum variance explained = 1.11%, $p = 6.2 \times 10^{-22}$, a 24% increase from ISGC1 (Table S22). Figure 2 presents a forest plot of the genetic correlations of the EUR GWAS meta-analyses of suicide attempt with several physical and mental health phenotypes, as well as one control phenotype (body mass index, BMI). Significant shared genetic covariation of EUR SA with smoking ($r_G = 0.46$, SE = 0.03, $p = 8.06 \times 10^{-63}$), ADHD ($r_G = 0.55$, SE = 0.04, $p = 2.98 \times 10^{-41}$), risk tolerance ($r_G = 0.32$, SE = 0.02, $p = 1.34 \times 10^{-59}$), and chronic pain ($r_G = .45$, SE = 0.03, $p = 9.50 \times 10^{-50}$) were observed both before and after conditioning on MDD and PTSD. Significant positive genetic correlations of neuroticism, schizophrenia, bipolar disorder, and self-harm ideation with SA ($r_G = 0.45$ SE = 0.03, $p = 1.0 \times 10^{-52}$; $r_G = 0.43$, SE = 0.03, $p = 1.32 \times 10^{-55}$; $r_G = 0.48$, SE = 0.04, $p = 1.81 \times 10^{-37}$; $r_G = 0.83$, SE = 0.06, $p = 1.94 \times 10^{-51}$) did not remain significant after conditioning on both MDD & PTSD.

For completeness of comparison across cohorts and phenotypic subgroups (SA versus SD), genetic correlation estimates for phenotypes are presented in Table S23 using the European GWAS summary statistics from 1) ISGC + MVP, 2) ISGC only, 3) MVP only, 4) ISGC without suicide death, 5) ISGC suicide death only (the Utah Suicide Study, current N = 4,692 EUR

suicide deaths and 20,702 controls), and 6) conditioning on MDD and PTSD for MVP, ISGC, and MVP + ISGC. LDSC jackknife tests of differences between these genetic correlation estimates are presented in Table S24, and more exhaustive comparison of phenome-wide r_G and genetic causal proportion analyses, with the European ancestry GWAS meta-analysis, are provided in Table S25. Genetic causal proportion analyses implicated several non-psychiatric genetic risks in EUR SA, including particulate air matter pollution exposure (pm 2.5), smoking exposures, and pulmonary health factors. Risk factors with significant partial genetic causality estimates are presented in Table S25.

Discussion

This study presents the largest GWAS meta-analysis of SA to date, incorporating multiple ancestries and expanding the set of GWS loci from four to 12. Discovery of three of the novel GWS loci, and improved out-of-sample PRS prediction across ancestry, was only possible with the aggregation of all ancestral cohorts. For the first time, we show that implicated genes are highly expressed in brain tissue, enriched in pathways related to gene regulation and transcription, cellular response to stress, DNA repair, and immunologic signatures, and are shared with epidemiological risk factors. Genetic correlation and causal proportion analyses implicate a number of non-psychiatric genetic risks in SA, including pulmonary health factors. We also provide important evidence that a significant proportion of the common variant genetic architecture of SA is shared across large civilian and veteran populations with disparate demographics.

One advantage of combining the ISGC with MVP was the opportunity to examine genetic effects across heterogeneous cohorts. For example, the sample composition and ascertainment across the ISGC is predominantly civilian and international, with a large proportion of females (7). A number of the ISGC samples from the Psychiatric Genomics Consortium cohorts (Table 1) are collected from individuals with major psychiatric disorders, representing a more clinical population. In contrast, the MVP cohorts are predominantly male (8), and all are military veterans ascertained through the U.S. Department of Veterans Affairs (VA) healthcare system. The consistency of SA common variant genetic architecture across EUR MVP and ISGC cohorts indicates that power may be further enhanced by combining future cohorts with differing ascertainments.

As expected, the increase in sample size, and resulting increase in power, led to the identification of several new GWS loci and improved out-of-sample PRS prediction—across ancestries—relative to the previous ISGC-only analyses. The loci identified in this study implicate genes expressed in brain. Genes associated with SA in this study are highly enriched among psychiatric phenotypes and overall health and wellness risk factors for SA. Brain is the predominant tissue enriched for associated genes, and there is also significant enrichment in pituitary gland, consistent with previous association of SA with hypothalamic-pituitary-adrenal system dysregulation (42). In addition, the enrichment of pathways related to epigenetics and gene regulation and transcription suggest that epigenetic modifications, such as DNA methylation, may play a role in modulating the effect of SA-associated genetic variants. However, epigenetic pathways were only enriched in EUR GWAS, pointing to the potential importance and varied impact of epigenetic mechanisms in diverse biological systems that may contribute to SA risk. Pathways enriched in the multi-ancestry GWAS were absent of histone-coding genes, and contained protein-coding genes mapped from GWS loci such as *FURIN, FES,* and *DRD2*. These multi-ancestry pathway results, while harder to interpret, may be more generalizable to the global population.

Drug target enrichment results suggest that SA risk is associated with the targets of antipsychotic and antidepressant drug classes. One explanation may be that psychiatric symptoms associated with SA risk are also associated with these drug targets, though the direction of any association of drugs with risk cannot be assumed and is not directly tested here. The SMR analysis of EUR results implicated *FES* and *TIAF1* in SA. *FES* has been previously implicated in cross-ancestry schizophrenia (41).

Genetic correlations of SA with ADHD, smoking, pain, and risk tolerance remained significant after conditioning SA on both MDD and PTSD, while schizophrenia, bipolar disorder, and neuroticism did not. This suggests a potential role for health factors in SA risk that are both shared with and distinct from psychiatric disorders, as proposed in Mann & Rizk's stress diathesis model (43) of suicidal behavior based on clinical and biological studies. The suicide diathesis includes altered decision-making that may be more pronounced in the context of ADHD and smoking, and may be aggravated by sleep problems. Pain is associated with the stress domain of suicidal behavior, and is also associated with increased access to prescription opioids. Overall, this study leverages genetic data to examine important risk phenotypes that may or may not be present in medical records.

Some limitations of this study should be considered. First, a meta-analysis of such a large number of diverse cohorts, with different assessments of SA, could reduce statistical power by increasing heterogeneity. Our analyses remain still more conservative with the inclusion of age and sex covariates in three of the ISGC cohorts and MVP. However, GWAS of the primary datasets typically produced significant—and high—genetic correlation estimates. GWS loci produced similar effect sizes across cohorts and across fixed and meta-regression models (correlations of EUR and all-ancestry GWS effect sizes across models exceeded 0.99). Indeed, the apparent consistency of genetic architecture across EUR ISGC and MVP cohorts is important given marked demographic and ascertainment differences.

This study also provides GWAS meta-analyses specific to African American and East Asian ancestries. The lack of GWS loci specific to these SA meta-analyses underscores a strong need for greater ancestral diversity and representation in suicide genetics research. With high variability of sample sizes of individual ISGC and MVP ancestral cohorts (case ns ranging from 115 to 9,196) some GWAS yielded h^2 and r_G estimates, while others did not. Variability in r_G indicates that increasing the examination of non-European ancestries in the future will significantly increase the generalizability of the genetic risk signals identified from studies of suicide phenotypes and the portability of polygenic scores. Importantly, broader ancestral representation—particularly from population-dense areas like India, Western Asia, and the Global South—will be critical for improving the rigor and generalizability of GWAS results in future research.

Implicated genes and established genetic relationships with ADHD, smoking, and risk tolerance help to inform our understanding of biological contributions to risk of SA. From a clinical standpoint, impulsivity, smoking status, and risk-taking behaviors are intuitive co-morbid indicators of suicide risk. Genetic causal proportion analyses implicate these and other health factors—pulmonary and cardiovascular—in risk for SA. And our preliminary comparison of genetic correlations across SA vs. SD GWAS cohorts appears to implicate risk tolerance in the severity of the suicide phenotype. Further study, comparing SD and SA with subjects with suicidal ideation, will allow for a comparison of those who think about suicide and those who act. Importantly, genetic risk for SA, calculated in new independent cohorts using these GWAS summary data, will contribute to a deeper understanding of the clinical implications of genetic

risk for suicide. The future addition of multiple ancestral cohorts is likely to yield continued discovery and increased opportunity for clinical translation.

References

1. Organization TWH: Suicide.
2. Organization TWH: Preventing suicide: A global imperative.
3. (SAMHSA) SAaMHSA.
4. Control CfD.
5. Franklin JC, Ribeiro JD, Fox KR, Bentley KH, Kleiman EM, Huang X, Musacchio KM, Jaroszewski AC, Chang BP, Nock MK. Risk factors for suicidal thoughts and behaviors: A meta-analysis of 50 years of research. Psychol Bull. 2017;143:187-232.
6. Voracek M, Loibl LM. Genetics of suicide: a systematic review of twin studies. Wien Klin Wochenschr. 2007;119:463-475.
7. Mullins N, Kang J, Campos AI, Coleman JRI, Edwards AC, Galfalvy H, Levey DF, Lori A, Shabalin A, Starnawska A, Su MH, Watson HJ, Adams M, Awasthi S, Gandal M, Hafferty JD, Hishimoto A, Kim M, Okazaki S, Otsuka I, Ripke S, Ware EB, Bergen AW, Berrettini WH, Bohus M, Brandt H, Chang X, Chen WJ, Chen HC, Crawford S, Crow S, DiBlasi E, Duriez P, Fernandez-Aranda F, Fichter MM, Gallinger S, Glatt SJ, Gorwood P, Guo Y, Hakonarson H, Halmi KA, Hwu HG, Jain S, Jamain S, Jimenez-Murcia S, Johnson C, Kaplan AS, Kaye WH, Keel PK, Kennedy JL, Klump KL, Li D, Liao SC, Lieb K, Lilenfeld L, Liu CM, Magistretti PJ, Marshall CR, Mitchell JE, Monson ET, Myers RM, Pinto D, Powers A, Ramoz N, Roepke S, Rozanov V, Scherer SW, Schmahl C, Sokolowski M, Strober M, Thornton LM, Treasure J, Tsuang MT, Witt SH, Woodside DB, Yilmaz Z, Zillich L, Adolfsson R, Agartz I, Air TM, Alda M, Alfredsson L, Andreassen OA, Anjorin A, Appadurai V, Soler Artigas M, Van der Auwera S, Azevedo MH, Bass N, Bau CHD, Baune BT, Bellivier F, Berger K, Biernacka JM, Bigdeli TB, Binder EB, Boehnke M, Boks MP, Bosch R, Braff DL, Bryant R, Budde M, Byrne EM, Cahn W, Casas M, Castelao E, Cervilla JA, Chaumette B, Cichon S, Corvin A, Craddock N, Craig D, Degenhardt F, Djurovic S, Edenberg HJ, Fanous AH, Foo JC, Forstner AJ, Frye M, Fullerton JM, Gatt JM, Gejman PV, Giegling I, Grabe HJ, Green MJ, Grevet EH, Grigoroiu-Serbanescu M, Gutierrez B, Guzman-Parra J, Hamilton SP, Hamshere ML, Hartmann A, Hauser J, Heilmann-Heimbach S, Hoffmann P, Ising M, Jones I, Jones LA, Jonsson L, Kahn RS, Kelsoe JR, Kendler KS, Kloiber S, Koenen KC, Kogevinas M, Konte B, Krebs MO, Landen M, Lawrence J, Leboyer M, Lee PH, Levinson DF, Liao C, Lissowska J, Lucae S, Mayoral F, McElroy SL, McGrath P, McGuffin P, McQuillin A, Medland SE, Mehta D, Melle I, Milaneschi Y, Mitchell PB, Molina E, Morken G, Mortensen PB, Muller-Myhsok B, Nievergelt C, Nimgaonkar V, Nothen MM, O'Donovan MC, Ophoff RA, Owen MJ, Pato C, Pato MT, Penninx B, Pimm J, Pistis G, Potash JB, Power RA, Preisig M, Quested D, Ramos-Quiroga JA, Reif A, Ribases M, Richarte V, Rietschel M, Rivera M, Roberts A, Roberts G, Rouleau GA, Rovaris DL, Rujescu D, Sanchez-Mora C, Sanders AR, Schofield PR, Schulze TG, Scott LJ, Serretti A, Shi J, Shyn SI, Sirignano L, Sklar P, Smeland OB, Smoller JW, Sonuga-Barke EJS, Spalletta G, Strauss JS, Swiatkowska B, Trzaskowski M, Turecki G, Vilar-Ribo L, Vincent JB, Volzke H, Walters JTR, Shannon Weickert C, Weickert TW, Weissman MM, Williams LM, Wray NR, Zai CC, Ashley-Koch AE, Beckham JC, Hauser ER, Hauser MA, Kimbrel NA, Lindquist JH, McMahon B, Oslin DW, Qin X, Major Depressive Disorder Working Group of the Psychiatric Genomics C, Bipolar Disorder Working Group of the Psychiatric Genomics C, Eating Disorders Working Group of the Psychiatric Genomics C, German Borderline Genomics C, Workgroup MVPSE, Program VAMV,

Agerbo E, Borglum AD, Breen G, Erlangsen A, Esko T, Gelernter J, Hougaard DM, Kessler RC, Kranzler HR, Li QS, Martin NG, McIntosh AM, Mors O, Nordentoft M, Olsen CM, Porteous D, Ursano RJ, Wasserman D, Werge T, Whiteman DC, Bulik CM, Coon H, Demontis D, Docherty AR, Kuo PH, Lewis CM, Mann JJ, Renteria ME, Smith DJ, Stahl EA, Stein MB, Streit F, Willour V, Ruderfer DM. Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biol Psychiatry. 2022;91:313-327.

8. Kimbrel NA, Ashley-Koch AE, Qin XJ, Lindquist JH, Garrett ME, Dennis MF, Hair LP, Huffman JE, Jacobson DA, Madduri RK, Trafton JA, Coon H, Docherty AR, Kang J, Mullins N, Ruderfer DM, Program VAMV, Workgroup MVPSE, International Suicide Genetics C, Harvey PD, McMahon BH, Oslin DW, Hauser ER, Hauser MA, Beckham JC. A genome-wide association study of suicide attempts in the million veterans program identifies evidence of pan-ancestry and ancestry-specific risk loci. Mol Psychiatry. 2022;27:2264-2272.

9. Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, Whitbourne S, Deen J, Shannon C, Humphries D, Guarino P, Aslan M, Anderson D, LaFleur R, Hammond T, Schaa K, Moser J, Huang G, Muralidhar S, Przygodzki R, O'Leary TJ. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214-223.

10. Sullivan PF, Agrawal A, Bulik CM, Andreassen OA, Borglum AD, Breen G, Cichon S, Edenberg HJ, Faraone SV, Gelernter J, Mathews CA, Nievergelt CM, Smoller JW, O'Donovan MC, Psychiatric Genomics C. Psychiatric Genomics: An Update and an Agenda. Am J Psychiatry. 2018;175:15-27.

11. Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, Daly MJ, Bustamante CD, Kenny EE. Human Demographic History Impacts Genetic Risk Prediction across Diverse Populations. Am J Hum Genet. 2017;100:635-649.

12. Docherty AR, Shabalin AA, DiBlasi E, Monson E, Mullins N, Adkins DE, Bacanu SA, Bakian AV, Crowell S, Chen D, Darlington TM, Callor WB, Christensen ED, Gray D, Keeshin B, Klein M, Anderson JS, Jerominski L, Hayward C, Porteous DJ, McIntosh A, Li Q, Coon H. Genome-Wide Association Study of Suicide Death and Polygenic Prediction of Clinical Antecedents. Am J Psychiatry. 2020;177:917-927.

13. Hoffmire C, Stephens B, Morley S, Thompson C, Kemp J, Bossarte RM. VA Suicide Prevention Applications Network: A National Health Care System-Based Suicide Event Tracking System. Public Health Rep. 2016;131:816-821.

14. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics C, Patterson N, Daly MJ, Price AL, Neale BM. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47:291-295.

15. Fang H, Hui Q, Lynch J, Honerlaw J, Assimes TL, Huang J, Vujkovic M, Damrauer SM, Pyarajan S, Gaziano JM, DuVall SL, O'Donnell CJ, Cho K, Chang KM, Wilson PWF, Tsao PS, Program VAMV, Sun YV, Tang H. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. Am J Hum Genet. 2019;105:763-772.

16. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.

17. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190-2191.

18. Luo Y, Li X, Wang X, Gazal S, Mercader JM, Me Research T, Consortium STD, Neale BM, Florez JC, Auton A, Price AL, Finucane HK, Raychaudhuri S. Estimating heritability and its enrichment in tissue-specific gene sets in admixed populations. Hum Mol Genet. 2021;30:1521-1534.

19. Nock MK, Borges G, Bromet EJ, Alonso J, Angermeyer M, Beautrais A, Bruffaerts R, Chiu WT, de Girolamo G, Gluzman S, de Graaf R, Gureje O, Haro JM, Huang Y, Karam E, Kessler RC, Lepine JP, Levinson D, Medina-Mora ME, Ono Y, Posada-Villa J, Williams D. Cross-

national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry. 2008;192:98-105.

20. Brown BC, Asian Genetic Epidemiology Network Type 2 Diabetes C, Ye CJ, Price AL, Zaitlen N. Transethnic Genetic-Correlation Estimates from Summary Statistics. Am J Hum Genet. 2016;99:76-88.

21. Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC, Hemani G, Tansey K, Laurin C, Early G, Lifecourse Epidemiology Eczema C, Pourcain BS, Warrington NM, Finucane HK, Price AL, Bulik-Sullivan BK, Anttila V, Paternoster L, Gaunt TR, Evans DM, Neale BM. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. Bioinformatics. 2017;33:272-279.

22. Ahmedani BK, Peterson EL, Hu Y, Rossom RC, Lynch F, Lu CY, Waitzfelder BE, Owen-Smith AA, Hubley S, Prabhakar D, Williams LK, Zeld N, Mutter E, Beck A, Tolsma D, Simon GE. Major Physical Health Conditions and Risk of Suicide. Am J Prev Med. 2017;53:308-315.

23. Fazel S, Runeson B. Suicide. N Engl J Med. 2020;382:266-274.

24. Hubel C, Gaspar HA, Coleman JRI, Finucane H, Purves KL, Hanscombe KB, Prokopenko I, investigators M, Graff M, Ngwa JS, Workalemahu T, Eating Disorders Working Group of the Psychiatric Genomics C, Major Depressive Disorder Working Group of the Psychiatric Genomics C, Schizophrenia Working Group of the Psychiatric Genomics C, Tourette Syndrome/Obsessive-Compulsive Disorder Working Group of the Psychiatric Genomics C, O'Reilly PF, Bulik CM, Breen G. Genomics of body fat percentage may contribute to sex bias in anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet. 2019;180:428-438.

25. Haworth S, Kho PF, Holgerson PL, Hwang LD, Timpson NJ, Renteria ME, Johansson I, Cuellar-Partida G. Assessment and visualization of phenome-wide causal relationships using genetic data: an application to dental caries and periodontitis. Eur J Hum Genet. 2021;29:300-308.

26. Nievergelt CM, Maihofer AX, Klengel T, Atkinson EG, Chen CY, Choi KW, Coleman JRI, Dalvie S, Duncan LE, Gelernter J, Levey DF, Logue MW, Polimanti R, Provost AC, Ratanatharathorn A, Stein MB, Torres K, Aiello AE, Almli LM, Amstadter AB, Andersen SB, Andreassen OA, Arbisi PA, Ashley-Koch AE, Austin SB, Avdibegovic E, Babic D, Baekvad-Hansen M, Baker DG, Beckham JC, Bierut LJ, Bisson JI, Boks MP, Bolger EA, Borglum AD, Bradley B, Brashear M, Breen G, Bryant RA, Bustamante AC, Bybjerg-Grauholm J, Calabrese JR, Caldas-de-Almeida JM, Dale AM, Daly MJ, Daskalakis NP, Deckert J, Delahanty DL, Dennis MF, Disner SG, Domschke K, Dzubur-Kulenovic A, Erbes CR, Evans A, Farrer LA, Feeny NC, Flory JD, Forbes D, Franz CE, Galea S, Garrett ME, Gelaye B, Geuze E, Gillespie C, Uka AG, Gordon SD, Guffanti G, Hammamieh R, Harnal S, Hauser MA, Heath AC, Hemmings SMJ, Hougaard DM, Jakovljevic M, Jett M, Johnson EO, Jones I, Jovanovic T, Qin XJ, Junglen AG, Karstoft KI, Kaufman ML, Kessler RC, Khan A, Kimbrel NA, King AP, Koen N, Kranzler HR, Kremen WS, Lawford BR, Lebois LAM, Lewis CE, Linnstaedt SD, Lori A, Lugonja B, Luykx JJ, Lyons MJ, Maples-Keller J, Marmar C, Martin AR, Martin NG, Maurer D, Mavissakalian MR, McFarlane A, McGlinchey RE, McLaughlin KA, McLean SA, McLeay S, Mehta D, Milberg WP, Miller MW, Morey RA, Morris CP, Mors O, Mortensen PB, Neale BM, Nelson EC, Nordentoft M, Norman SB, O'Donnell M, Orcutt HK, Panizzon MS, Peters ES, Peterson AL, Peverill M, Pietrzak RH, Polusny MA, Rice JP, Ripke S, Risbrough VB, Roberts AL, Rothbaum AO, Rothbaum BO, Roy-Byrne P, Ruggiero K, Rung A, Rutten BPF, Saccone NL, Sanchez SE, Schijven D, Seedat S, Seligowski AV, Seng JS, Sheerin CM, Silove D, Smith AK, Smoller JW, Sponheim SR, Stein DJ, Stevens JS, Sumner JA, Teicher MH, Thompson WK, Trapido E, Uddin M, Ursano RJ, van den Heuvel LL, Van Hooff M, Vermetten E, Vinkers CH, Voisey J, Wang Y, Wang Z, Werge T, Williams MA, Williamson DE, Winternitz S, Wolf C, Wolf EJ, Wolff JD, Yehuda R, Young RM, Young KA, Zhao H, Zoellner LA, Liberzon I, Ressler KJ,

Haas M, Koenen KC. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat Commun. 2019;10:4558.

27. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, Coleman JRI, Hagenaars SP, Ward J, Wigmore EM, Alloza C, Shen X, Barbu MC, Xu EY, Whalley HC, Marioni RE, Porteous DJ, Davies G, Deary IJ, Hemani G, Berger K, Teismann H, Rawal R, Arolt V, Baune BT, Dannlowski U, Domschke K, Tian C, Hinds DA, andMe Research T, Major Depressive Disorder Working Group of the Psychiatric Genomics C, Trzaskowski M, Byrne EM, Ripke S, Smith DJ, Sullivan PF, Wray NR, Breen G, Lewis CM, McIntosh AM. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343-352.

28. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, Robinson MR, McGrath JJ, Visscher PM, Wray NR, Yang J. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun. 2018;9:224.

29. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011;88:76-82.

30. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR. A global reference for human genetic variation. Nature. 2015;526:68-74.

31. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.

32. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8:1826.

33. Consortium GT, Laboratory DA, Coordinating Center -Analysis Working G, Statistical Methods groups-Analysis Working G, Enhancing Gg, Fund NIHC, Nih/Nci, Nih/Nhgri, Nih/Nimh, Nih/Nida, Biospecimen Collection Source Site N, Biospecimen Collection Source Site R, Biospecimen Core Resource V, Brain Bank Repository-University of Miami Brain Endowment B, Leidos Biomedical-Project M, Study E, Genome Browser Data I, Visualization EBI, Genome Browser Data I, Visualization-Ucsc Genomics Institute UoCSC, Lead a, Laboratory DA, Coordinating C, management NIHp, Biospecimen c, Pathology, e QTLmwg, Battle A, Brown CD, Engelhardt BE, Montgomery SB. Genetic effects on gene expression across human tissues. Nature. 2017;550:204-213.

34. Gaspar HA, Breen G. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. Sci Rep. 2017;7:12460.

35. Wagner AH, Coffman AC, Ainscough BJ, Spies NC, Skidmore ZL, Campbell KM, Krysiak K, Pan D, McMichael JF, Eldred JM, Walker JR, Wilson RK, Mardis ER, Griffith M, Griffith OL. DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 2016;44:D1036-1044.

36. Wu Y, Zeng J, Zhang F, Zhu Z, Qi T, Zheng Z, Lloyd-Jones LR, Marioni RE, Martin NG, Montgomery GW, Deary IJ, Wray NR, Visscher PM, McRae AF, Yang J. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. Nat Commun. 2018;9:918.

37. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard ME, Wray NR, Visscher PM, Yang J. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48:481-487.

38. de Klein N, Tsai EA, Vochteloo M, Baird D, Huang Y, Chen CY, van Dam S, Oelen R, Deelen P, Bakker OB, El Garwany O, Ouyang Z, Marshall EE, Zavodszky MI, van Rheenen W, Bakker MK, Veldink J, Gaunt TR, Runz H, Franke L, Westra HJ. Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain-related diseases. Nat Genet. 2023.

39. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10:1776.

40. Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, Groza T, Gunes O, Hall P, Hayhurst J, Ibrahim A, Ji Y, John S, Lewis E, MacArthur JAL, McMahon A, Osumi-Sutherland D, Panoutsopoulou K, Pendlington Z, Ramachandran S, Stefancsik R, Stewart J, Whetzel P, Wilson R, Hindorff L, Cunningham F, Lambert SA, Inouye M, Parkinson H, Harris LW. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. Nucleic Acids Res. 2023;51:D977-D985.

41. Ikeda M, Takahashi A, Kamatani Y, Momozawa Y, Saito T, Kondo K, Shimasaki A, Kawase K, Sakusabe T, Iwayama Y, Toyota T, Wakuda T, Kikuchi M, Kanahara N, Yamamori H, Yasuda Y, Watanabe Y, Hoya S, Aleksic B, Kushima I, Arai H, Takaki M, Hattori K, Kunugi H, Okahisa Y, Ohnuma T, Ozaki N, Someya T, Hashimoto R, Yoshikawa T, Kubo M, Iwata N. Genome-Wide Association Study Detected Novel Susceptibility Genes for Schizophrenia and Shared Trans-Populations/Diseases Genetic Effect. Schizophr Bull. 2019;45:824-834.

42. Pfennig A, Kunzel HE, Kern N, Ising M, Majer M, Fuchs B, Ernst G, Holsboer F, Binder EB. Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. Biol Psychiatry. 2005;57:336-342.

43. Mann JJ, Rizk MM. A Brain-Centric Model of Suicidal Behavior. Am J Psychiatry. 2020;177:902-916.

Figure Titles and Legends

Figure 1: Manhattan plot of multi-ancestry GWAS meta-analysis of suicide attempt. The *x*-axis shows genomic position and the *y*-axis shows statistical significance as –log$_{10}$(P value). The horizontal line shows the genome-wide significance threshold (P<5.0x10^{-8}). Labels represent the nearest gene to the index SNP. Regional plots of the eight genome-wide significant loci across ancestries and the four genome-wide significant loci in Europeans are presented in Supplementary Figures S3-S14.

Figure 2: Forest plot of genetic correlations of the multi-ancestry GWAS meta-analyses of suicide attempt with physical and mental health phenotypes. The *x*-axis presents genetic correlation values with 95% confidence intervals (CI), and the *y*-axis presents the discovery GWAS for multiple phenotypes. ISGC = International Suicide Genetics Consortium meta-analysis; ISGC + MVP = the primary meta-analysis including GWAS from both ISGC and Million Veterans Program sets of cohorts; ISGC + MVP | MDD & PTSD = the combined GWAS meta-analysis of both cohorts conditioning on major depressive disorder and post-traumatic stress disorder.

Table 1. Summary of GWAS cohorts and ancestries

Cohort	Attempt/Death	Ascertainment	Cases	Controls
EUR Ancestries				
Army STARRS	Attempt	Military	670	10,637
Australian Genetics of Depression Study	Attempt	Psychiatric	2,792	20,193
Columbia University	Attempt & Death	Psychiatric	577	1,233
Genetic Investigation of Suicide and SA (GISS)	Attempt	Psychiatric	660	660
German Borderline Genomics Consortium	Attempt	Psychiatric	481	1,653
iPSYCH	Attempt	Population	7,003	52,227
Janssen	Attempt	Psychiatric	255	1,684
Million Veteran Program	Attempt	Military	9,196	287,370
Psychiatric Genomics Consortium BIP	Attempt	Psychiatric	3,214	17,642
Psychiatric Genomics Consortium ED	Attempt	Psychiatric	170	5,070
Psychiatric Genomics Consortium MDD	Attempt	Psychiatric	1,528	16,626
Psychiatric Genomics Consortium SCZ	Attempt	Psychiatric	1,640	7,112
UK Biobank	Attempt	Population	2,433	334,766
University of Utah	Death	Population	4,692	20,702
Yale-Penn	Attempt	Psychiatric	475	1,817
Total			**35,786**	**779,392**
EAS Ancestries				
CONVERGE Consortium	Attempt	Psychiatric	1,148	6,515
Kobe University	Death	Population	746	14,049
Million Veteran Program	Attempt	Military	115	4,082
Total			**2,009**	**24,646**
AA Ancestries				
Grady Trauma Project	Attempt	General medical	669	4,473
Million Veteran Program	Attempt	Military	3,507	74,306
Yale-Penn	Attempt	Psychiatric	629	2,902
Total			**4,805**	**81,681**
LAT Ancestries				
Million Veteran Program	Attempt	Military	**1,271**	**29,306**
Multi-ancestry Total			**43,871**	**915,025**

Note: EUR = European, EAS = East Asian, AA = African/African American, LAT = Latin American, BIP = bipolar disorder, ED = eating disorders, MDD = major depressive, disorder, SCZ = schizophrenia

Table 2: Results from meta-analyses of suicide attempt showing the index SNP from each genome-wide significant locus

CHR	Index SNP	BP	Locus Start..Stop	Nearest gene (distance to index SNP in kb)	P	OR	SE	A1	A2	Direction
Multi-Ancestry										
1	rs3791129	44480093	44,462,155..44,497,134	*SLC6A9* (0.0)	1.22E-09	1.055	0.009	G	A	+-+++++--+-+?+++?+??+
3	rs7649709	173129819	173,113,742..174,012,162	*NLGN1* (0.0)	2.32E-08	1.054	0.010	A	C	++++++-++++?++-+++++
6	rs62404522	19307114	19,068,774..19,180,711	*LOC101928519* (-76.4)	1.68E-09	1.067	0.011	C	T	+--+++--++++++-+-++++
7	rs62474683	115020725	114,763,653..114,871,409	*LINC01392* (-149.3)	8.72E-12	1.054	0.008	A	G	+-++++-+++++++++--++++
11	rs7131627	113299829	113,280,327..113,346,120	*DRD2* (0.0)	6.2E-11	1.053	0.008	G	A	+++++--++++++++++++++
12	rs17485141	24213634	23,682,438..24,715,425	*SOX5* (0.0)	1.54E-08	1.049	0.009	C	T	+++-+++++++++-++++++++++
13	rs9525171	96908223	96,742,361..97,491,816	*HS6ST3* (0.0)	8.07E-09	1.044	0.008	C	G	+-+++++--+-+++++-+++
15	rs17514846	91416550	91,411,818..91,426,687	*FURIN* (0.0)	1.81E-09	1.048	0.008	C	A	++++++++++-+-+++?+?+++
EUR Ancestry										
1	rs2503185	66461401	66,258,193..66,840,262	*PDE4B* (0.0)	3.42E-08	1.047	0.008	A	G	++++++---+++++
6	rs35869525	26946687	29,640,168..30,152,231	--MHC--	2.18E-08	1.089	0.015	C	T	+?-+-+++-++++++
14	rs850261	57346423	57,278,724..57,398,026	*OTX2-AS1* (0.0)	1.37E-08	1.049	0.008	A	G	++-+-+++++++++-
22	rs2284000	37053338	36,956,904..37,099,797	*CACNG2* (0.0)	1.98E-08	1.055	0.010	C	G	+++++++-+-++?++

Note: CHR = chromosome, SNP = single nucleotide polymorphism, BP = GRCh37 base pair position, kb = kilobases, OR = odds ratio, SE = standa other allele, EUR = European, $N_{Cohorts}$ = number of cohorts included, N_{Total} = Total cases and controls, N_{Eff} = total effective sample size, MHC = ma

Figure 1: Manhattan plot of multi-ancestry GWAS meta-analysis of suicide attempt. The *x*-axis shows genomic position and the *y*-axis shows statistical significance as –log$_{10}$(P value). The horizontal line shows the genome-wide significance threshold (P<5.0x10^{-8}). Labels represent the nearest gene to the index SNP. Regional plots of the eight genome-wide significant loci across ancestries and the four genome-wide significant loci in Europeans are presented in Supplementary Figures S3-S14.

Figure 2: Forest plot of genetic correlations of the multi-ancestry GWAS meta-analyses of suicide attempt with physical and mental health phenotypes. The *x*-axis presents genetic correlation values with 95% confidence intervals (CI), and the *y*-axis presents the discovery GWAS for multiple phenotypes. ISGC = International Suicide Genetics Consortium meta-analysis; ISGC + MVP = the primary meta-analysis including GWAS from both ISGC and Million Veterans Program sets of cohorts; ISGC + MVP | MDD & PTSD = the combined GWAS meta-analysis of both cohorts conditioning on major depressive disorder and post-traumatic stress disorder.